Drug Safety Newsletter 48th Edition
06 July 2012
Topics covered in this edition of the newsletter include:
- Topical tacrolimus (Protopic) – Important recommendations for appropriate use to minimise risks
- Strontium (Protelos and Osseor) – Updates to product information on risks of venous thromboembolism and severe allergic skin reaction
- Vernakalant (Brinavess) – Risk of severe hypotension and bradycardia
- Fingolimod (Gilenya) – Updated recommendations on cardiovascular monitoring during treatment initiation
- Direct Healthcare Professional Communications published on the IMB website since the last Drug Safety Newsletter
- Blue dye – containing products – Risk of serious allergic reactions with off-label use
- Antipsychotics – Risk of extra-pyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy
Drug Safety Newsletter 48th Edition